Purpose: Metastatic relapse of triple-negative breast cancer (TNBC) within 2 years of diagnosis is associated with particularly aggressive disease and a distinct clinical course relative to TNBCs that relapse beyond 2 years. We hypothesized that rapid relapse TNBCs (rrTNBC; metastatic relapse or death <2 years) reflect unique genomic features relative to late relapse (lrTNBC; >2 years).
INTRODUCTION
Triple negative breast cancer (TNBC) is an aggressive breast cancer subtype defined by lack of targetable estrogen receptor (ER), progesterone receptor (PR) and HER2. 1 TNBC accounts for 15% of breast cancer cases yet is responsible for 35% of breast cancer related deaths. 1, 2 TNBCs tend to present with higher grade, large size, and often involve lymph nodes at diagnosis. 3 TNBCs are more likely to develop distant rather than local recurrence compared to hormone receptor-positive counterparts and spreads more frequently to lung and brain and less frequently to bone. 2, 4 Understanding determinants of distant relapse is imperative as the median overall survival after diagnosis of metastatic disease was historically only 13-17 months 2, 5 and even among patients with PD-L1 positive TNBC receiving chemo-immunotherapy remains 25 months.
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The existing TNBC subsets/groupings provide a critical framework for understanding intrinsic genomic characteristics but are only associated with modest differences in patient survival. Clinically, we know that the majority of patients diagnosed with TNBC are long-term survivors. 1, 2, 7 Among the 20-30% of TNBCs who develop metastatic disease, a subset have an aggressive phenotype associated with rapid relapse, therapeutic resistance, and poor prognosis while others have a relatively late relapse, associated with more indolent or treatment responsive disease. 7 To more accurately understand the differences in patient outcome in TNBC, we sought to investigate TNBCs defined by timing of outcome: rapid versus late versus no relapse.
Advances in sequencing technology have facilitated comprehensive molecular profiling of breast cancers, including subsets such as TNBC. 8, 9 A major challenge for TNBC is inter-tumor heterogeneity, thought to be an important contributor to therapeutic resistance. A landmark transcriptional analysis of over 500 primary TNBCs revealed six subtypes of TNBC with distinct expression profiles. 10, 11 An integrated genomic analysis of TNBCs presented a unifying theory with four main TNBC subsets: 1) basal-like, immune-activated; 2) basal-like, immune suppressed; 3) luminal androgen receptor subtype: non-basal subtype with few CNAs; 4) mesenchymal: genomically unstable with fibroblast/EMT phenotype. 12 In addition, genomic analyses demonstrate high frequency of TP53 mutation, present in more than 75% of TNBCs, as well as mutations in PIK3CA in approximately 25% of cases. [12] [13] [14] TNBCs also reflect widespread copy number alterations, suggesting that lack of genomic integrity is a key mutational process in TNBC. [12] [13] [14] Clinical datasets may be limited in size, so accurate predictive modeling is crucial in a disease such as TNBC that has multiple distinct subsets. 15 To be successful, predictive model needs to be able to learn from a small input and extract high-level, accurate information. 15 There is growing implementation of various machine learning approaches to many areas of research including molecular subtypes of breast cancer 16, 17 and pathologic image analyses, such as detection of lymph node metastases in women with breast cancer. 18 Determining the best approach for predictive modeling depends on size of data set, type of features, and outcome.
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In this study, we identify distinct genomic features among primary TNBCs categorized based on outcome: rapid (rrTNBC), late (lrTNBC) and no relapse (nrTNBC). Using a comparative modeling approach, we show that machine learning approaches provides an optimal predictor of rapid relapse for primary TNBCs.
METHODS

Patient and Tumor Characteristics
Patient-specific data were obtained from TCGA
13
, METABRIC 20, 21 , and from our published metaanalysis (as described previously). 8 These variables included age at diagnosis, grade, stage at diagnosis, pathologic receptor status (estrogen receptor (ER), progesterone receptor (PR), and HER2), response to neoadjuvant chemotherapy (where available), and distant metastasis-free or overall survival. Triple-negative breast cancer was defined as being negative for ER, PR, and HER2.Pathologic receptor status was 'positive' or 'negative' based on the following definitions: for ER and PR immunohistochemistry (IHC), 0 was defined as 'negative', 2-3 was defined as 'positive', and an IHC of 1 was considered indeterminate. For HER2, a FISH HER2/CEP17 ratio of greater than 2.0 was defined as 'positive'. Chemotherapy response was categorized as pathologic complete response (pCR) or residual disease (RD) based on study-reported outcomes.
Genomic Data
For data from the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC), normalized gene expression data, copy number data, and somatic mutation data for 171 cancerrelated genes were obtained from the publicly available European Genome-phenome Archive (IDs EGAD00010000210 and EGAD0001000021) and associated publications 21, 22 . Copy number segmented data files were processed using GISTIC2.0
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. For data from TCGA, breast cancer gene expression data, GISTIC copy number data, and somatic mutation data were obtained from the UCSC cancer browser (now XENAbrowser; version 2015-02-24) . Gene expression data from published studies of breast cancer patients prior to neoadjuvant chemotherapy were compiled as previously described. 8 
Gene Expression Signatures, Expression-Based Subtypes, and Inferred Immune Subsets
Given gene expression data from multiple studies and disparate platforms, gene expression data for all TNBCs for each dataset (METABRIC n=287, TCGA n=160, neoadjuvant dataset n=446) were extracted and quantile normalized within TNBCs from each study then median centered. Due to complexities of comparing single gene expression or differential expression across datasets/platforms/batches, we only evaluated summary expression metrics (e.g. signatures, intrinsic subtypes, CIBERSORT proportions). Gene expression signatures were compiled from published studies, as previously described. 8 We determined PAM50 intrinsic breast cancer subtype using the 'Bioclassifier' package from Parker et al after balancing TNBC data with an equal number of ERpositive cases for each dataset. 24 Triple-negative breast cancer (TNBC) subtype was determined using the TNBCtype tool. 10, 25 Proportion of infiltrating immune cell subsets were calculated using the CIBERSORT algorithm. 
Model Performance
To evaluate model performance, we assessed each group as a positive outcome (rrTNBC versus all others; lrTNBC vs all others; nrTNBC vs all others) using receiver-operator characteristic (ROC) curves. We used multi_roc function in multiROC 30 to compute micro-average area under the curve (AUC) of three ROC curves to evaluate the overall performance of the models. To avoid sampling bias, we calculated the average AUC on the 30% test data for 10 independent runs.
Statistical Analysis
All statistical analyses were performed in R version 3.4.1. Contrasts in patient and tumor characteristics were evaluated using Pearson chi-squared tests. for CIBERSORT and mutation signatures were evaluated using logistic regression, and for CNAs and mutations were evaluated using Fisher exact tests. Data visualization was made using ggplot2.
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RESULTS
Defining Rapid versus Late versus No Relapse Triple-Negative Breast Cancer
From three large cohorts with primary breast cancer genomic data -TCGA, 13 METABRIC, 20, 21 and our prior breast cancer gene expression meta-analysis 8 -we identified 893 TNBCs from a total of 4473 breast cancer cases. For our analyses, we included patients with at least 60 months of follow-up or those with a distant metastasis-free survival (DMFS) event prior to our 60-month cutoff, leaving a total of 453 TNBCs in our evaluable dataset. Of these, 453 had gene expression data, 317 had copy number data, and 317 had mutation data. (Figure 1A) .
We assessed the percentage of total DMFS events each year ( Figure 1B) . In this dataset, over 20%
of DMFS events occurred within the first two years after diagnosis, categorized as 'rapid relapse' (rrTNBC). While most DMFS events occurred within the first five years after diagnosis, 1-3% of events occurred annually in years 6-10 with sporadic events beyond 10 years (lrTNBC). Our main goal was to identify differences among TNBCs with clinically distinct outcomes, so we visualized DMFS for our relapse categorization ( Figure 1C ) in comparison with DMFS for existing intrinsic expression-based subtype approaches PAM50 24 ( Figure 1D ) or Lehmann/Pietenpol TNBCtype 10 ( Figure 1D ) within the same cohort. The Lehmann/Pietenpol TNBCtype (log-rank p=0.01) but not PAM50 was associated with significant differences in DMFS. The strikingly different visualized outcomes suggested that our relapse categorization does, in fact, identify truly distinct subsets based on outcome when compared to approaches that focus on intrinsic features.
Patient and Tumor Characteristics
We evaluated the association of clinical, pathologic, and intrinsic expression subtype with rapid vs.
late vs. no relapse status ( Table 1) . There was no significant difference in age at diagnosis or grade;
however, rrTNBCs were significantly more likely to be higher stage (Chi-square p=1.9e-10). The majority of patients were basal-like PAM50 subtype (78%); however, lrTNBCs were significantly more likely to be non-basal (non-basal: rrTNBC 18%, lrTNBC 29%, nrTNBC 20%, Chi-square p=0.03).
Lehmann/Pietenpol TNBC subtype also reflected significant differences across groups (Chi-square p=0.02), although each subtype was represented within each relapse category: the immunomodulatory phenotype was highest in nrTNBC (16% rrTNBC, 16% lrTNBC, 24% nrTNBC),luminal androgen receptor was highest in lrTNBC (9% rrTNBC, 16% lrTNBC, 9% nrTNBC), and basal-like 2 was highest in rrTNBC (15% rrTNBC, 9% lrTNBC, 6% nrTNBC). A subset of patients in this cohort (127/453; 28.0%) had data on response to neoadjuvant chemotherapy (NAC). As anticipated, those patients with rrTNBC or lrTNBC were significantly more likely to have residual disease (RD) after neoadjuvuant chemotherapy (93% and 94% RD, respectively), relative to those with nrTNBC (51% RD; Chi-square p=1.9e-7).
Response to Neoadjuvant Chemotherapy and Survival in TNBC: Immune and Expression Signatures
Response to NAC is known to be a robust prognostic biomarker in TNBC 32 and, in this cohort, RD after NAC was among the clinicopathologic features most strongly associated with rapid and late versus no relapse ( Table 1 ). The patients with data on response to NAC all had whole transcriptome data but no available mutation or copy number data, so we sought to understand expression features associated with NAC response and DMFS. We calculated a score for 125 published gene expression signatures and evaluated the association of each signature with NAC response (pathologic complete response versus RD) by simple linear regression and hazard ratio for each signature using DMFS.
Signatures were grouped by phenotype as previously described 8 (n=127 patients; Figure 2A ).
Immune signatures were associated with better prognosis and most were also associated with improved response to NAC. Proliferation signatures tended to be associated with improve*ed response to NAC, as we have previously described 8 , yet there was variable association with DMFS.
Estrogen receptor/HER2 signatures were associated with poor response to NAC but better DMFS. Figure 1A) .
Expression Signatures in Rapid versus Late versus No Relapse TNBC
To assess pathways and phenotypes associated with rapid vs. late vs. no relapse, a score was calculated for 125 published gene expression signatures across the entire dataset. Visual observation of all signatures or only the quarter with the greatest variance did not yield any clear patterns (Supplementary Figure 1B) . Evaluating each signature individually across the three groups revealed Figure 2A-B Figure 2C) , however, neutrophils were significantly higher in rrTNBC (ANOVA FDR p=0.001) while resting mast cells were significantly lower in lrTNBC (ANOVA FDR p=0.003).
Mutations and Copy Number Alterations
In this cohort, 70% (317/453) of patients had data on single nucleotide variant/mutation data on 171
cancer-related genes and whole genome CNAs. 21 Only a small subset of patients (11.7%; 53/453) had whole exome mutation data so we focused on the 171 cancer-related genes to ensure adequate statistical power. When evaluating general mutational features, there was no significant difference in mutations per megabase (ANOVA p=0.64; Figure 4A ) nor percent genome altered by copy number (ANOVA p=0.96; Figure 4B ).
We first compared the frequency of alteration for each mutation and cytoband (for CNAs) for relapse (rrTNBC + lrTNBC) versus nrTNBC ( Figure 4C ) given low frequency of mutation for most genes.
There were no genes that were significantly different after multiple testing when comparing relapse versus no relapse but PIK3CA mutations were more frequent in relapse relative to nrTNBC; and PTEN, ARID1A, and RYR2 mutations enriched in nrTNBC relative to rrTNBC (Fisher exact nominal p<0.05). We then compared rrTNBC versus lrTNBC ( Figure 4D ) and found that rrTNBC were significantly more likely to harbor a mutation in TP53 compared to lrTNBC patients (Fisher exact FDR p=0.009). There were no other genes that were significantly different when comparing rapid vs. late vs. no relapse after multiple test correction (Supplementary Figure 3A) . Among CNAs, the copy number landscape was similar across all three groups (Supplementary Figure 3B) and there were no significantly altered genes or regions among rapid vs. late vs. no relapse after multiple test correction. There were several regions that demonstrated enrichment within specific groups (nominal p<0.05), including: 3q28 gain, 8p11 gain, and 21q21-22 gain enriched in relapse relative to nrTNBC; 5p12-13 loss and 6p25 loss enriched in nrTNBC relative to relapse; 6q23-24 loss enriched in lrTNBC relative to rrTNBC; and 15q23-26 loss enriched in rrTNBC relative to lrTNBC (Figure 4C-D) .
Optimal clinical and multi-'omic model of rapid versus late versus no relapse in TNBC
Having identified discrete clinical, expression, immune, mutation, and copy number features among primary TNBCs with distinct clinical outcomes, we sought to develop an optimal, multi-'omic predictive model for rrTNBC versus lrTNBC versus nrTNBC. As has been applied previously in complex breast cancer data (Figure 5A ). We included any feature present in all samples (n=312) with a nominal p<0.05, which resulted in a total of 77 clinical, expression, immune, mutation, and copy number features ( Figure 5A ). Our total multi-'omic dataset was divided into 70% training and 30% validation cohorts, independently sampled for each cross validation (10-fold cross validation). We assessed each model's performance using three separate receiver-operator characteristics (ROCs) (rrTNBC as positive, lrTNBC as positive, and nrTNBC as positive) due to 3-level classification. We then integrated these into a single ROC curve via micro-averaging ( Figure   5B ). All models performed relatively well, with highest average AUC 0.772 (SVM) and lowest average AUC 0.681 (ANN) ( Figure 5C) . When comparing models, SVM had the highest average AUC, significantly higher than all other models (all Wilcoxon rank sum p<0.05), followed by RF and multinomial. As a sensitivity analysis, we repeated our approach using only the 18 most significant features that were all FDR p<0.05 in descriptive statistics and found that using fewer features led to similar average AUC (range 0.695 to 0.748), with random forest performing best (all Wilcoxon rank sum p<0.05) followed by SVM and multinomial (Supplementary Figure 3C) . Collectively, our data support the categorization by Burstein, et al 12 and suggest that 'rapid relpase'
DISCUSSION
TNBCs are likely enriched for the 'basal-like immune suppressed' phenotype.
Clinically, multi-'omic models could serve as an adjunct to neoadjuvant chemotherapy response to predict patients at high risk of rapid relapse to guide more aggressive therapy while identifying those likely to be cured (even with residual disease) to avoid unnecessary toxicity of additional treatment.
Given our interest to understand what genomic features contribute, we considered the best way to overcome the significant challenge extracting important features of machine learning algorithms.
Because multi-'omic data has clear features that can be extracted, 50 we first identified the relatively few specific features that were significantly different across subsets (77 features from >35,000 initial data points) then built models based on a priori feature identification. This approach identified key genomic features up-front and led to overall good performance of multiple models but may miss unexpected interactions among raw features.
Stage at diagnosis was strongly associated with rapid relapse in univariate analyses and in the multinomial model (where feature contribution could be extracted), stage was the feature contributing most to the model. This suggests that despite our efforts to use complex biological data, stage remains critical. One hypothesis is that stage at diagnosis captures non-biological features such as socioeconomic or demographics, including income, education, insurance, and access to care.
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Race/ethnicity is complex, 56-58 was largely unavailable in the included datasets, and warrants further study. 59, 60 We are currently evaluating the association of sociodemographic features and race/ethnicity with rrTNBC in other data sources.
While this study presents promising methods to categorize TNBC relapse it does possess some limitations. The retrospective nature of our data means that patients might not perfectly fit the definitions we assigned, for example, a small number of late relapse events may occur in the nrTNBC group after 5 years. We incorporated genomic data from multiple studies, generated using multiple platforms, and over years. While we have attempted to account for this through standard normalization approaches and analysis only of summary statistics (e.g. expression signatures not individual genes), batch/platform effects and computational analyses could impact our results.
Therapy for TNBC has changed over the past 2-3 years, including widespread incorporation of capecitabine after neoadjuvant chemotherapy for residual disease based on CREATE-X 61 and recent FDA approval of immunotherapy for metastatic, PD-L1 positive TNBC.
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In conclusion, we offer a new definition for 'rapid relapse' TNBC and provide evidence that rrTNBC reflects a distinct clinical entity characterized by unique genomic features. Predictive modeling may identify patients at high risk for 'rapid relapse' and offers potential to guide additional therapy or clinical trials for these high-risk patients. 
